Perioperative risks of bevacizumab and other biologic agents for hepatectomy: theoretical or evidence based?
Bilchik
Anton J
AJ
Hecht
J Randolph
JR
D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D000068258:Bevacizumab; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D015179:Colorectal Neoplasms / Q000473:pathology; D019317:Evidence-Based Medicine; D006498:Hepatectomy / Q000379:methods*; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery*; D008115:Liver Regeneration / Q000187:drug effects*; D051379:Mice; D019990:Perioperative Care; D011292:Premedication / Q000009:adverse effects*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab